DFDouglas R. Fredrick

Douglas R. Fredrick

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Douglas R. Fredrick has a total of 6 co-authors. Here are the top co-authors by number of shared publications:

  • David A. Hollander

    Department of Ophthalmology, The University of California, San Francisco, San Francisco, California, USA

    1 shared publication
  • Edward L. Howes

    Department of Ophthalmology, The University of California, San Francisco, San Francisco, California, USA

    1 shared publication
  • Ilona J. Frieden

    Department of Dermatology University of California San Francisco California USA

    1 shared publication
  • Jesse B. Biebesheimer

    Department of Ophthalmology, University of California, San Francisco 94143-0730, USA

    1 shared publication
  • T M Ranchod

    Santa Clara Valley Medical Center, San Jose, California, USA

    1 shared publication
  • William F. Hoyt

    Department of Ophthalmology, The University of California, San Francisco, San Francisco, California, USA

    1 shared publication

Latest Publications

  • Open Access

    Corticosteroid treatment of periorbital haemangioma of infancy: a review of the evidence

    by T M Ranchod, I J Frieden, D R Fredrick

    Aim: To systematically review the literature for corticosteroid treatment of periorbital haemangioma of infancy (HOI) and determine the relative efficacy and safety of oral, topical and intralesional corticosteroids. Methods: PubMed and the Cochrane Library were queried using keywords, and further articles were obtained by reviewing bibliographies. Inclusion and exclusion criteria were applied to create a subset of literature for analysis. Results: Systematic review revealed 81 original reports of periorbital HOI cases treated with steroids. Most studies and case series failed to document refractive error or visual acuity before and after treatment. Of cases meeting inclusion criteria, five patients received topical steroids and 25 patients received intralesional steroids. Patients receiving intralesional injections tended to demonstrate reduced astigmatism at follow up after treatment (21 of 28). The lack of studies with relevant objective ophthalmological end points prevented statistical meta-analysis. Conclusion: Intralesional injections may reduce refractive error, while the efficacy of topical steroids is unclear. Studies measuring objective ophthalmic data before and after treatment are sparse, and more studies are needed to determine the relative efficacy of different steroids. There are insufficient data to estimate the incidence of steroid side effects in patients treated with steroids for periorbital HOI or complications of intralesional injections in particular.


  • The pseudopapilledema of neonatal-onset multisystem inflammatory disease

    by David A. Hollander, William F. Hoyt, Edward L. Howes, Douglas R. Fredrick


  • Myopia

    by Douglas R Fredrick

    Methods This review article was prepared by searching Medline for citations of articles in English using the keyword “myopia.” In addition, abstracts from the annual meetings of the Association for Research in Vision and Ophthalmology were reviewed. Myopia, commonly referred to as shortsightedness, is a common cause of visual disability throughout the world. The World Health Organization has grouped myopia and uncorrected refractive error with cataract, macular degeneration, infectious disease, and vitamin A deficiency among the leading causes of blindness and vision impairment in the world.1 People with myopia can be classified in two groups, those with low to modest degrees of myopia (referred to as “simple” or “school” myopia, 0 to 6 dioptres) and those with high or pathological myopia (greater than 6 dioptres). Simple myopia can be corrected with spectacles or contact lenses, whereas “high” (pathological) myopia is often associated with potentially blinding conditions such as retinal detachment, macular degeneration, and glaucoma (fig 1). The prevalence of myopia varies by country and by ethnic group, reaching as high as 70-90% in some Asian populations. 2 3 In Japan it is estimated that more than one million people suffer from vision impairment associated with high myopia.4 According to epidemiological evidence the prevalence of myopia is increasing, especially in Asian populations.5 The prevalence of pathological myopia is estimated at 1-3% in population based studies.6 In addition to the human cost of visual disability, there is a profound economic cost to society. In the United States, for example, the treatment of myopia costs an estimated $250m (£173m, €281m) per year.7 As the prevalence of simple myopia increases, the incidence of pathological myopia may also increase. Since no current treatments can reverse the structural changes of pathological myopia, preventing myopia has long been a goal of ophthalmologists and scientists researching vision. Understanding the mechanisms and factors that affect ocular growth is prerequisite to development of these therapeutic strategies.